Praxis Precision Medicines, Inc.
NASDAQ:PRAXBiotechnology
+$12.13 today
- Market cap
- $8.69B
- Beta
- 2.75
- P/E (TTM)
- -25.0
- EPS (TTM)
- -$11.31
Volume 0.63M
Average 0.45M
Returns on capital
Praxis Precision Medicines, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-34.5%
avg -111.4%
ROIC
-37.1%
avg -105.6%
ROA
-32.3%
avg -85.2%
Analysis
ROA is currently the strongest return metric at -32.3% versus its period average of -85.2%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Marcio Souza | President, Chief Executive Officer & Director | USD 2.65M | 47 | 0 | <0.01% |
Timothy Edwin Kelly | Chief Financial Officer & Treasurer | USD 1.18M | 53 | 31.17K | 0.15% |
Alex Nemiroff | General Counsel & Secretary | USD 1.03M | 47 | 26.01K | 0.12% |
Karl Hansen | Chief Technical Operations Officer | — | — | — | — |
Alyssa J. S. Wyant | Chief Regulatory & Quality Officer | — | 51 | — | — |
Megan T. Sniecinski | Chief Operating Officer | — | 45 | — | — |
Brian Spar | Chief of Staff | — | — | — | — |
Orrin Devinsky | Head of Clinical Strategy | — | 68 | — | — |
Steven Petrou | Co-Founder and President of Research & Development | — | — | — | — |
Kelly McCue | Chief People Officer | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jul 8, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
18
$11.08M
Net Transaction Value
−$11.08M
Net selling
Most Active
DeSimone Jill
12 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Jun 24, 26Jun 24, 2026 | DeSimone Jill Direct | Sell | $97.7K$97,699.20 |
| Jun 24, 26Jun 24, 2026 | DeSimone Jill Direct | Sell | $209.5K$209,521.86 |
| Jun 24, 26Jun 24, 2026 | DeSimone Jill Direct | Sell | $382.2K$382,221.32 |
| Jun 24, 26Jun 24, 2026 | DeSimone Jill Direct | Sell | $309.1K$309,073.62 |
| Jun 24, 26Jun 24, 2026 | DeSimone Jill Direct | Sell | $544.1K$544,055.75 |
| Jun 24, 26Jun 24, 2026 | DeSimone Jill Direct | Sell | $890.2K$890,202.56 |
| Jun 24, 26Jun 24, 2026 | DeSimone Jill Direct | Sell | $314.1K$314,081.32 |
| Jun 24, 26Jun 24, 2026 | DeSimone Jill Direct | Sell | $158.1K$158,086.15 |
| Jun 24, 26Jun 24, 2026 | DeSimone Jill Direct | Sell | $402.8K$402,758.38 |
| Jun 24, 26Jun 24, 2026 | DeSimone Jill Direct | Sell | $264.2K$264,245.08 |
1–10 of 18
Summary
Insiders reported 0 buys worth $0.00 and 18 sells worth $11.08M over the last 12 months. That adds up to net selling of $11.08M. DeSimone Jill was the most active insider with 12 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A7 analysts |
| Revenue | N/A | N/A | N/A | N/A9 analysts |
| Net Income | N/A | N/A | N/A | N/A9 analysts |
| EBIT | N/A | N/A | N/A | N/A9 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does Praxis Precision Medicines, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about PRAX's management, answered from reported figures.
Who manages PRAX?
Praxis Precision Medicines, Inc. (PRAX) lists 10 active executives. The top listed executive is Karl Hansen, Chief Technical Operations Officer.
Are PRAX insiders buying or selling?
Recent insider activity shows net buying of $70.77M.
Continue the stock analysis
Jump to another research area for this company.